EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting osteoclast-derived DPP4 alleviates inflammation-mediated ectopic bone formation in ankylosing spondylitis

Seung Hoon Lee, Kyu Hoon Lee, Dongju Kim, Chanhyeok Jeon, Min Whangbo, Hye-Ryeong Jo, Jeehee Youn, Chang-Hun Lee, Sung Hoon Choi, Ye-Soo Park, Bora Nam, Sungsin Jo iD und 1 weitere

Arthritis Research & Therapy · 25.02.2025 · 27 (1)

DOI: 10.1186/s13075-025-03474-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Research & Therapy, online erschienen am 25.02.2025. Verfasst von Seung Hoon Lee und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hanyang University Institute for Rheumatology Research (HYIRR), Hanyang University, Seoul, 04763, Korea. Hauptthemen laut MEDLINE: Spondylitis, Ankylosing, Osteoclasts, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Research Foundation of Korea, the Korea Healthy Industry Development Institute, Soonchunhyang University Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by ectopic bone formation. The anti-inflammatory function of dipeptidyl peptidase-4 (DPP4) inhibitor has been reported in bone metabolism, but its utility in AS has not previously been investigated. METHODS: We assessed DPP4 level in serum, synovial fluid, and facet joint tissue of AS patients. Additionally, we investigated the effect of a DPP4 inhibitor in an experimental AS model using curdlan-injected SKG mice. Following curdlan injection, SKG mice were orally administered a DPP4 inhibitor three times per week for 5 weeks and observed clinical arthritis scores, and analyzed by micro-CT. Furthermore, osteoclast precursor cells (OPCs) from curdlan-injected SKG mice were treated with DPP4 inhibitor and evaluated the inhibitory effects of this treatment in vitro. RESULTS: Soluble DPP4 level was elevated in the serum and synovial fluid of patients with AS compared to those in the control group. Expression of DPP4 increased gradually during human osteoclastogenesis and was high in mature osteoclasts. Oral administration of a DPP4 inhibitor resulted in a decrease in thickness of the hind paw, clinical arthritis scores, and enthesitis at the ankle in curdlan-injected SKG mice compared to the vehicle group. Micro-CT data revealed a significant reduction in inflammation-induced low bone density in the DPP4 inhibitor group. Moreover, treatment with a DPP4 inhibitor significantly reduced osteoclast differentiation of OPC in addition to decreasing expression of osteoclast differentiation markers. CONCLUSION: Our findings suggest that inhibiting DPP4 may have a therapeutic effect on inflammation-mediated ectopic bone formation in AS patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spondylitis, AnkylosingOsteoclastsDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsOsteogenesisAnimalsMiceHumansMaleInflammationFemaleAdultMiddle AgedSynovial Fluid

Stichwörter der Autor:innen

Curdlan-injected SKG miceDipeptidyl peptidase-4 (DPP4) inhibitorInflammation-mediated ectopic bone formationOsteoclasts

Substanzen

Dipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsDPP4 protein, human

Autor:innen und Institutionen

  • Hanyang University Institute for Rheumatology Research (HYIRR), Hanyang University, Seoul, 04763, Korea.
  • Department of Rehabilitation Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, 04763, Korea.
  • Department of Anatomy & Cell Biology, College of Medicine, Hanyang University, Seoul, 04763, South Korea.
  • Department of Orthopaedic Surgery, Hanyang University Seoul Hospital, Seoul, 04763, South Korea.
  • Department of Orthopaedic Surgery, Guri Hospital, Hanyang University College of Medicine, Guri, 11923, South Korea.
  • Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 222-1 Wangsimni-ro, Seongdong-gu, Seoul, 04763, Republic of Korea.

ORCID-Profile: Sungsin Jo, Tae-Hwan Kim

Förderung

  • the National Research Foundation of Korea
  • the Korea Healthy Industry Development Institute
  • Soonchunhyang University Research Fund

Zitieren

APA

Lee, S. H., Lee, K. H., Kim, D., Jeon, C., Whangbo, M., Jo, H. R., Youn, J., Lee, C. H., Choi, S. H., Park, Y. S., Nam, B., Jo, S., & Kim, T. H. (2025). Targeting osteoclast-derived DPP4 alleviates inflammation-mediated ectopic bone formation in ankylosing spondylitis. Arthritis Research & Therapy, 27(1). https://doi.org/10.1186/s13075-025-03474-2

Vancouver

Lee SH, Lee KH, Kim D, Jeon C, Whangbo M, Jo HR, et al. Targeting osteoclast-derived DPP4 alleviates inflammation-mediated ectopic bone formation in ankylosing spondylitis. Arthritis Research & Therapy. 2025;27(1). doi:10.1186/s13075-025-03474-2

BibTeX
@article{Lee2025,
  author = {Lee, Seung Hoon and Lee, Kyu Hoon and Kim, Dongju and Jeon, Chanhyeok and Whangbo, Min and Jo, Hye-Ryeong and Youn, Jeehee and Lee, Chang-Hun and Choi, Sung Hoon and Park, Ye-Soo and Nam, Bora and Jo, Sungsin and Kim, Tae-Hwan},
  title = {Targeting osteoclast-derived DPP4 alleviates inflammation-mediated ectopic bone formation in ankylosing spondylitis},
  journal = {Arthritis Research & Therapy},
  year = {2025},
  volume = {27},
  number = {1},
  doi = {10.1186/s13075-025-03474-2}
}
Kostenlos starten →